| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -40,669 | -34,197 |
| Stock-based compensation | 6,594 | 3,610 |
| Gain on settlement of accounts payable | 626 | - |
| Depreciation expense | 28 | - |
| Impairment of acquired in-process research and development intangible assets | 16,514 | 16,514 |
| Research and development tax credit receivable | 523 | 424 |
| Other tax receivable | 532 | 322 |
| Prepaid expenses | 141 | 174 |
| Accounts payable and accrued liabilities related parties | - | 159 |
| Other assets | 667 | 491 |
| Accounts payable and accrued liabilities | 962 | 1,132 |
| Accretion of debt discount | - | 0 |
| Deferred liabilities | -517 | -6 |
| Prepaid expenses related party | - | 0 |
| Operating lease liabilities | -61 | - |
| Net cash used in operating activities | -19,638 | -14,199 |
| Purchase of equipment | 899 | 706 |
| Net cash used in investing activities | -899 | -706 |
| Repayments of debt | - | 0 |
| Net proceeds from sale of common stock and warrants | 27,544 | 27,544 |
| Exercise of warrants for cash | 1 | 1 |
| Net cash provided by financing activities | 27,545 | 27,545 |
| Impact on cash from foreign currency translation | -196 | -188 |
| Net increase (decrease) in cash and cash equivalents | 6,812 | 12,452 |
| Cash and cash equivalents at beginning of period | 20,922 | - |
| Cash and cash equivalents at end of period | 27,734 | - |
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)